Financials
| Final Results | Feb. 04, 2026 |
| 3rd Quarter Results | Oct. 29, 2025 |
| 2nd Quarter Results | Jul. 30, 2025 |
| 1st Quarter Results | Apr. 30, 2025 |
| GSK plc 2024 Annual Report on Form 20-F | Mar. 03, 2025 |
| GSK publishes Annual Report 2024 | Feb. 27, 2025 |
| 2024 Annual Financial Report | Feb. 27, 2025 |
Proxies
| Notice of AGM | Mar. 25, 2026 |
| Result of AGM | May. 07, 2025 |
| GSK Proxy Form 2025 | Mar. 24, 2025 |
| GSK AGM Notice 2025 | Mar. 24, 2025 |
| Notice of AGM | Mar. 24, 2025 |
| Result of AGM | May. 08, 2024 |
| GSK Proxy Form 2024 | Mar. 25, 2024 |
Ownership Update
| Transaction in Own Shares | Mar. 31, 2026 |
| Transaction in Own Shares | Mar. 30, 2026 |
| Transaction in Own Shares | Mar. 27, 2026 |
| Transaction in Own Shares | Mar. 26, 2026 |
| Director/PDMR Shareholding | Mar. 25, 2026 |
| Transaction in Own Shares | Mar. 25, 2026 |
| Transaction in Own Shares | Mar. 24, 2026 |
Announcements
| Bepirovirsen accepted for review in China | Mar. 30, 2026 |
| Exdensur approved for severe asthma in China | Mar. 30, 2026 |
| Bepirovirsen accepted for review by the EMA | Mar. 27, 2026 |
| Admission to Trading | Mar. 23, 2026 |
| GSK Lung Cancer ADC Gets Japan Orphan Drug Status | Mar. 23, 2026 |
| Lynavoy (linerixibat) approved by US FDA | Mar. 19, 2026 |
| US FDA approves Arexvy for adults 18-49 AIR | Mar. 13, 2026 |
Prospectuses
| GSK plc;GLAXOSMITHKLINE CAPITAL PLC;GSK Capital B.V.;GSK Capital K.K - Base prospectus (debt) | Sep. 07, 2022 |